Or
Contact Us5-Fluorouracil — 5-FU for short. It has been in oncology for decades. That is not a reason to dismiss it. It stays in active use because certain tumor types respond to it and it slots into combinations that have a long track record.
Patients rarely encounter it as a standalone drug. It tends to appear as part of something bigger — FOLFOX, FOLFIRI, FOLFIRINOX, or running alongside radiation in rectal cancer treatment. The regimen name tells most of the story. The 5-FU inside it is one component.
It goes in through a drip. Some protocols use a short infusion in the clinic. Others run it through a pump the patient takes home, delivering the drug slowly over two days. Both are 5-FU. The experience of treatment is different. That distinction should be explained before the first cycle, not discovered at the end of the first appointment.
To copy their DNA, dividing cells need specific building blocks. 5-FU mimics one of those building blocks closely enough to get taken up — then blocks the enzyme that needs it. Copying stalls. The cell cannot divide properly and eventually stops.
It hits fast-dividing cells hardest. That is the tumor. It is also the gut lining, mouth, and bone marrow. Those tissues replace themselves constantly, which is why mouth sores, diarrhea and blood count drops show up as side effects — not a malfunction, just the drug reaching tissue it was not meant to spare.
How it is given changes which effects dominate. A fast bolus infusion and a slow continuous infusion deliver the same molecule through a different pharmacological window. The toxicity pattern shifts. Mouth sores and diarrhea are more prominent with continuous infusion. The oncologist chooses the schedule for a reason, and understanding that reason is part of being prepared.
5-FU turns up across several cancer types, most of them gastrointestinal.
Diagnosis is a starting point. Stage, molecular profile, treatment goal, previous lines and physical condition all shape whether 5-FU belongs right now and in which form.
A few situations put it naturally into the conversation.
5-FU and capecitabine get discussed together often. They are related but not the same thing. Which one fits depends on the regimen structure, the tumor type and whether the patient can manage a reliable tablet schedule. One is not automatically a substitute for the other — that comparison needs to happen explicitly.
Before the first infusion the team needs more than the diagnosis and the regimen name.
DPD testing deserves specific attention. A patient with reduced DPD activity given a standard dose of 5-FU can develop severe and life-threatening toxicity. Testing is not universal in all countries but where available it should be discussed. Even without testing, knowing the warning signs — early severe diarrhea, mouth sores, sudden deterioration within the first days — matters.
Two main formats exist. A short infusion given in the clinic as part of a cycle. Or a prolonged infusion delivered through a portable pump, usually over 46 hours, then disconnected at the clinic or sometimes by the patient at home.
Pump patients go home with treatment still running. Before that happens they need to know how the pump works, what a blockage or leak looks like, who to call and when to go in. This is not information to absorb on the day of the first infusion.
During treatment the team monitors:
Cardiac symptoms during or after 5-FU are uncommon but they are the one side effect that needs immediate attention rather than a call at the next convenient moment. Chest tightness or pressure during an infusion means stopping the drip and contacting the team straight away.
5-FU’s side effect profile depends partly on how it is given.
DPD deficiency changes everything. Without enough of that enzyme, 5-FU accumulates rather than clearing normally. The result is severe toxicity arriving fast — heavy diarrhea, deep mouth ulcers, significant marrow suppression within the first few days of treatment. That pattern is a signal. The team needs to hear about it immediately, not at the next planned visit.
Some symptoms cannot wait for a scheduled appointment.
Mouth sores that stop a patient from drinking lead to dehydration faster than most people expect. This is not a symptom to push through until the next scheduled visit. The team needs to know early enough to help.
Widely used does not mean universally safe. Several factors can make 5-FU the wrong choice or require significant adjustment.
Capecitabine converts to 5-FU inside the body. For some patients and some regimens it is the more practical choice. For others, infusional 5-FU is specifically what the protocol requires. The comparison is worth having explicitly rather than assuming one is simply a convenient substitute for the other.
Almost always yes. 5-FU rarely runs alone in current practice. Common combinations:
What 5-FU is paired with shapes the treatment experience significantly. FOLFOX brings neuropathy from oxaliplatin. FOLFIRI brings diarrhea from irinotecan. FOLFIRINOX is the most intensive of the three. The regimen name matters — not just the 5-FU component inside it.
Response is not measured after the first cycle. Imaging, markers and clinical assessment after several cycles give the picture. One scan or one PSA is rarely enough to draw conclusions either way.
If disease is clearly progressing, if toxicity is becoming unsafe, or if the original treatment goal no longer fits — the plan needs reviewing. 5-FU is one component of a strategy. When the strategy needs updating, that conversation should not be delayed.
Tel Aviv Medical Clinic offers oncology consultations and second opinions for patients on a 5-FU-based regimen or trying to understand which regimen fits their situation.
The consultation can cover:
We do not replace the treating doctor. We help the patient arrive at the next conversation with a clear picture of the options.
Capecitabine is a tablet. Once swallowed, the body converts it into 5-FU. The active molecule ends up being similar. The practical experience is completely different — one means a pump or clinic infusion, the other means tablets at home twice a day. Which one fits depends on the regimen, the tumor type, whether the protocol specifically requires infusional delivery, and whether the patient can manage a consistent oral schedule. Neither is automatically a substitute for the other — that choice should be explained rather than assumed.
DPD is an enzyme that breaks down fluoropyrimidines including 5-FU. Patients with reduced DPD activity cannot clear the drug at a normal rate. At a standard dose, the drug accumulates and causes severe toxicity — significant diarrhea, deep mouth ulcers, serious marrow suppression — appearing within the first days. Testing before treatment identifies patients at risk. Where testing is available, it is worth discussing. Where it is not, knowing the warning signs matters even more.
Understand it before you leave the clinic. Know what it looks like when it is running normally, what a blockage or disconnection looks like, what the alarm means, and who to call at any hour. If chest tightness or pain develops while the pump is running, disconnect it if you know how and call the team immediately — do not wait to see if it passes. A pump running at home means the team needs to be reachable and the patient needs to know how.
They range from mild discomfort to severe ulceration that makes eating or drinking painful or impossible. Severe mouth sores lead to dehydration faster than most patients expect. The team needs to know when mouth sores reach the point where drinking becomes difficult — not at the next scheduled visit, but at that point. Early intervention keeps a manageable problem from becoming a reason to stop treatment.
Pathology with molecular profile if available, recent imaging, the full treatment history with dates, the current regimen and schedule, recent bloods. If DPD testing has been done, bring those results. If there have been significant side effects — early severe diarrhea, mouth problems, cardiac symptoms — write down when they happened and how severe they were. That specific account is what makes a second opinion useful.
This page gives general medical information. It is not a personal treatment plan. 5-FU should be discussed only after review of the diagnosis, stage, DPD status, cardiac history, previous treatment and the patient’s overall condition.
Do not start, stop or change chemotherapy without your treating oncologist.
For consultation about 5-FU treatment:
📞 +972-73-374-6844
💬 WhatsApp: +972-52-337-3108
